“…MAPK signaling is the key in T cell development and activation (32) and acts as an upstream activator of NFAT (27Y30). Thus, by inhibition of the MAPK pathway, CNIs suppress the proliferation and function of T cells (35,36), which are prominent players in the cascade of alloreactivity leading to graft rejection (37,38). The proof that MAPK monitoring has clinical utility should come from a study that correlates this biomarker with the occurrence of rejection.…”